Inhibition of VAP‐1 with bromoethylamine attenuated both steatosis and inflammatory responses, indicating that targeting the oxidase activity of VAP‐1 may offer dual benefits for managing steatosis and inflammation. Here, AOC3 is linked to steatosis.